- Author:
Minju SONG
1
Author Information
- Publication Type:Review
- Keywords: Antiresorptive drugs; Bisphosphonate; Denosumab; Dental care; Osteonecrosis
- MeSH: Bone Density Conservation Agents; Bone Resorption; Denosumab; Dental Care; Dentists; Diphosphonates; Humans; Jaw; Oral and Maxillofacial Surgeons; Osteonecrosis; Osteoporosis
- From:Restorative Dentistry & Endodontics 2019;44(4):e42-
- CountryRepublic of Korea
- Language:English
- Abstract: Antiresorptive drugs (ARDs), such as bisphosphonates or denosumab, that prevent bone resorption are widely used in patients with osteoporosis or with cancer that has metastasized to the bones. Although osteonecrosis of the jaw (ONJ) is a well-documented complication of ARD use, the benefits ARDs outweigh the complication. Thus, research has focused on finding ways to prevent or reduce the risk of developing ONJ. Dentists, as part of a multi-professional team, have a critical role in preventing ONJ. However, many dentists tend to hesitate to provide dental care to patients with ONJ, or tend to think that it is a problem to be dealt with by oral surgeons. This review gives an overview of ARD-related ONJ and provides the guidelines for dental care in patients taking ARDs to lower the risk of developing ONJ.